RIGEL PHARMACEUTICALS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO EVALUATE THE IMPACT OF FOSTAMATINIB TREATMENT DURING HOSPITALIZATION RESULTING FROM ARDS ON LONG-TERM OUTCOMES INCLUDING CLINICAL, BIOMARKER, IMAGING, QOL, FUNCTIONAL AND LUNG FUNCTI
$749,999
| Recipient | RIGEL PHARMACEUTICALS INC UEI X7MHPBCMHFM3 |
|---|---|
| Award ID | 75A50123C00012 |
| Award amount | $749,999 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — Office of Assistant Secretary for Preparedness and Response |
| NAICS | 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) |
| PSC | AN15 |
| Start date | May 1, 2023 |
| End date | Oct 31, 2025 |
| Place of performance | SOUTH SAN FRANCISCO, CA |
| Record updated | Sep 6, 2024 |
View the official award record
More awards won by RIGEL PHARMACEUTICALS INC
65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS, FSS CONTRACT AWARD
Department of Veterans Affairs · $19,516,920 · Oct 15, 2023
Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.
Search open bids